Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Biocytogen, a China Animal Model CRO, Closes $77 Million Series D

publication date: Aug 8, 2019

Beijing Biocytogen, a CRO that provides gene-modified animal models for biomedical research, closed a $77 million Series D venture funding round. The D round was led by China Life Healthcare Fund and SDIC Venture Capital. Last year, the company raised $65 Million in a C round. Founded in 2008, Biocytogen has branches in Beijing, Haimen /Jiangsu, Shanghai and Boston. Bioocytogen generates custom gene-modified animal models/cell lines, breeds and produces animal models, and provides preclinical testing services for immunoncology molecules and therapeutic antibodies. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital